




>>Entry Name: Corticotrophin, BAN, INN

Synonym(s): α^{1-39} -Corticotropin (human), 9CI. Adrenocorticotrophin. Corticotropin. Adrenocorticotrophic hormone. ACTH. Adrenomone. Adrenocorticotropin. Acthar. Exacthin. Acton. Acthar. Humactid. Duracton



CAS Registry Number: 9002-60-2

Related CAS Registry Numbers(s): 581-05-5 2279-03-0 2791-05-1 4037-01-8 4086-29-7 4237-93-8 9061-27-2 10285-27-5 11088-21-4 12279-41-3 17179-80-5 18806-03-6 19253-97-5 19253-98-6 19405-50-6 24828-93-1 27844-05-9 33440-05-0 39319-42-1 54651-40-0 58232-12-5 61544-13-6 66795-39-9 77465-10-2 90014-90-7 92879-89-5 103812-42-6 120500-35-8

Molecular Formula: $\text{C}_{207}\text{H}_{308}\text{N}_{56}\text{O}_{58}\text{S}$

Molecular Weight: 4541.117

Accurate Mass: 4538.259384

Percentage Composition: C 54.75%; H 6.84%; N 17.27%; O 20.43%; S 0.71%

General Statement: Struct. of human corticotropin shown. Minor differences in sequence have been identified in corticotropins from other mammalian spp.

Biological Source: Endocrine hormone derived from pro-opiomelanotropin by proteolytic cleavage and released from the anterior lobe of the pituitary gland to cause release of several cortical hormones from the adrenal cortex. The amino terminal 1-19 sequence is necessary for corticotropic activity

Use/Importance: Has been used in the clinical treatment of rheumatoid arthritis and asthma and used diagnostically to investigate adrenocortical insufficiency

Other Data: Also used as a suspension with zinc hydroxide (Corticotropin-zinc hydroxide, INN)

Hazard & Toxicity: Systemic and adverse effects when used therapeutically. Exp. reprod. and teratogenic effects

Sigma: A4772

References:

- Graf, L. *et al.*, *Biochim. Biophys. Acta*, 1971, **6**, 415, (struct)
Sieber, P. *et al.*, *Helv. Chim. Acta*, 1972, **55**, 1243, (synth)
Yamashiro, D. *et al.*, *J.A.C.S.*, 1973, **95**, 1310, (synth)
Oleofson, W., *Pharmacol. Ther.*, 1975, **B1**, 459
Li, C.H. *et al.*, *Biochem. Biophys. Res. Commun.*, 1978, **81**, 900, (struct)
Schwyzer, R., *Ann. N.Y. Acad. Sci.*, 1979, **297**, 3, (rev)
Chang, A.C.Y. *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 1980, **77**, 4890, (cloning)
Reith, M.E.A. *et al.*, *Pharmacol. Ther.*, 1981, **12**, 449, (metab, rev)
Lintner, K. *et al.*, *Horm. Act. Brain Pept.: Struct. Funct.*, 1982, **45**, (rev, conformn)
Bennett, H.P.J. *et al.*, *J. Biol. Chem.*, 1983, **258**, 8108, (struct, isoln)
Jakubke, H.-D. *et al.*, *Angew. Chem., Int. Ed.*, 1985, **24**, 85, (rev)
Imura, H., *Clin. Endocrinol. Metab.*, 1985, **14**, 845, (rev)
Inouye, K. *et al.*, *Horm. Proteins Pept.*, 1987, **13**, 1; 59; 173, (formn)
Simpson, E.R. *et al.*, *Annu. Rev. Physiol.*, 1988, **50**, 427, (rev)
Snead, O.C., *Antiepileptic Drugs*, (Eds. Levy, R. *et al.*), Raven Press, New York, 1989, 905
Martindale, *The Extra Pharmacopoeia*, 30th edn., Pharmaceutical Press, 1993, 1461
Lewis, R.J., *Sax's Dangerous Properties of Industrial Materials*, 8th edn., Van Nostrand Reinhold, 1992, AES650